The U.S. Army Medical Research Acquisition Activity has recently announced intentions to award a sole-source contract to GlaxoSmithKline Export Ltd. for the purchase of 50 vials of IND IV Pentostam (Sodium Stibogluconate) for the U.S. Medical Material Development Activity, Fort Detrick, Md.
Pentostam is used to treat individuals who have acquired leishmaniasis (either cutaneous, mucocutaneous or visceral).
The current protocol is written and approved by the FDA specifically for Pentostam. The protocol is under Investigational New Drug application (IND) # 14,150.
Further details are available via Solicitation Number: W81XWH15T0168.
